Skip to content

Acupuncture and Relaxation Response for GI Symptoms and HIV Medication Adherence

Acupuncture and Relaxation Response for GI Symptoms and HIV Medication Adherence

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00545623
Enrollment
130
Registered
2007-10-17
Start date
2007-04-30
Completion date
2010-09-30
Last updated
2014-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV/AIDS, Alternative Medicine, Complementary Medicine

Brief summary

The aims of the study are to investigate individual, combined and added effects of acupuncture and the relaxation response in reducing gastrointestinal symptoms, improving medication adherence and quality of life among people living with HIV/AIDS. The study will also explore the mechanism of these therapeutic effects of acupuncture and the relaxation response.

Interventions

PROCEDUREAcupuncture

acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks

listening to CDs with verbal instructions of techniques to elicit relaxation response

OTHERsham acupuncture

sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
Boston University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Confirmed HIV-positive status or AIDS diagnosis 2. Self report of having at least one of the 6 GI symptoms: diarrhea, loose stools, gas/flatulence or bloating, abdominal pain, nausea, or vomiting that have persisted for at least 8 weeks. 3. Being on a stable antiretroviral regimen containing Nucleoside/nucleotide reverse transcriptase inhibitors and/or protease inhibitors- for at least 8 weeks.

Exclusion criteria

1. Incident diagnosis of any of the following conditions within the past month or during study period: Pneumocystis carinii pneumonia, Kaposi's sarcoma, Mycobacterium avian complex, Cytomegalovirus, Non-Hodgkins lymphoma, Lymphoma or other cancer, Pelvic inflammatory disease, AIDS-related dementia, Bacterial or other infection, Diabetes, Acute moderate or severe neutropenia, Cryptococcus, Progressive multifocal leukoencephalopathy, Idiopathic thrombocytopenic purpura. All of these conditions are major opportunistic infections or medical complications that may require hospitalization and additional pharmaceutical intervention. 2. GI diagnoses of irritable bowel syndrome, Crohn's Disease, parasites, any type of gastric ulcer or ulcerative colitis or cancer in any part of the gastrointestinal system. These are conditions not related to HIV diagnosis and could result in digestive problems similar to those we are investigating. 3. Onset of acute opportunistic infection. 4. Hemophilia or other bleeding disorder since that will make acupuncture treatment unsafe. 5. Pregnant women will be excluded since, although none of the acupuncture points or combinations are contraindicated in pregnancy, the presence of morning sickness could serve as a potential confounding factor. 6. Current users of acupuncture for treating GI symptoms. 7. Current practice of relaxation response. 8. Current enrollment in another clinical intervention study. 9. Cognitive impairment as measured by Mini Mental Status Examination (MMSE), a reliable and valid screening instrument for the detection of cognitive impairment, using a commonly used cut-off point of 24. 10. If use of Chinese herbs has been recently discontinued, a potential participant must have at least 2 weeks without herb use to be eligible for the study. Because use of herbs is occasionally accompanied by digestive disorders,a period of stabilizing is required before acupuncture treatment can be initiated. This washout period has been conservatively estimated by ACP staff herbalists to constitute a sufficient time for effects of herbs to cease.

Design outcomes

Primary

MeasureTime frameDescription
Changes in GI Symptom Per Intervention Session8 weeksWe used the GI symptom subscale of the Revised HIV Sign and Symptom Checklist (SSC-HIV) to measure the intensity (0-10) of the six targeted GI symptoms: diarrhea, loose stools, gas/bloating, abdominal pain, nausea and vomiting, with 0 indicating no symptom and 10 indicating most sever symptom. Rating changes per intervention session were estimated using a mixed effects regression model controlling for baseline ratings. Data of loose stools are presented here.

Countries

United States

Participant flow

Participants by arm

ArmCount
ACUP+RR
acupuncture + relaxation response CD Acupuncture: acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks Relaxation Response: listening to CDs with verbal instructions of techniques to elicit relaxation response
31
SHAM+RR
sham acupuncture + relaxation response CD Relaxation Response: listening to CDs with verbal instructions of techniques to elicit relaxation response
27
ACUP+EDU
acupuncture+education CD Acupuncture: acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
27
SHAM+EDU
sham acupuncture+education CD sham acupuncture: sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
30
Total115

Baseline characteristics

CharacteristicACUP+RRSHAM+RRACUP+EDUSHAM+EDUTotal
Age, Continuous47.2 years
STANDARD_DEVIATION 8.8
45.0 years
STANDARD_DEVIATION 7.1
47.1 years
STANDARD_DEVIATION 9.9
47.0 years
STANDARD_DEVIATION 8.2
46.6 years
STANDARD_DEVIATION 8.5
Region of Enrollment
United States
31 participants27 participants27 participants30 participants115 participants
Sex: Female, Male
Female
9 Participants9 Participants7 Participants9 Participants34 Participants
Sex: Female, Male
Male
22 Participants18 Participants20 Participants21 Participants81 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —
other
Total, other adverse events
5 / 325 / 315 / 332 / 34
serious
Total, serious adverse events
0 / 320 / 310 / 330 / 34

Outcome results

Primary

Changes in GI Symptom Per Intervention Session

We used the GI symptom subscale of the Revised HIV Sign and Symptom Checklist (SSC-HIV) to measure the intensity (0-10) of the six targeted GI symptoms: diarrhea, loose stools, gas/bloating, abdominal pain, nausea and vomiting, with 0 indicating no symptom and 10 indicating most sever symptom. Rating changes per intervention session were estimated using a mixed effects regression model controlling for baseline ratings. Data of loose stools are presented here.

Time frame: 8 weeks

Population: An intent-to-treat approach was used for analysis. That is all patients who had at least one data points were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
ACUP+RRChanges in GI Symptom Per Intervention Session-0.24 units on a scaleStandard Error 0.04
SHAM+RRChanges in GI Symptom Per Intervention Session-0.08 units on a scaleStandard Error 0.04
ACUP+EDUChanges in GI Symptom Per Intervention Session-0.09 units on a scaleStandard Error 0.04
SHAM+EDUChanges in GI Symptom Per Intervention Session-0.09 units on a scaleStandard Error 0.04

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026